New Models of Therapy: When Acute Leukemia Becomes Chronic

Biol Blood Marrow Transplant. 2015 Oct;21(10):1856-7. doi: 10.1016/j.bbmt.2015.07.011. Epub 2015 Jul 14.

Authors

Celalettin Ustun¹, Richard Stone², Daniel Weisdorf²

Affiliations

¹ Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. Electronic address: custun@umn.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

PMID: 26183079
DOI: 10.1016/j.bbmt.2015.07.011

No abstract available

Publication types

Letter

MeSH terms

Disease Progression
Fusion Proteins, bcr-abl / antagonists & inhibitors
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / enzymology
Maintenance Chemotherapy / methods
Mastocytosis, Systemic / drug therapy
Mastocytosis, Systemic / enzymology
Molecular Targeted Therapy / methods*
Mutation, Missense
Neoplasm Proteins / antagonists & inhibitors*
Point Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins c-kit / antagonists & inhibitors
Proto-Oncogene Proteins c-kit / genetics
Tandem Repeat Sequences
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
fms-Like Tyrosine Kinase 3 / genetics

Substances

Neoplasm Proteins
Protein Kinase Inhibitors
FLT3 protein, human
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-kit
fms-Like Tyrosine Kinase 3
Fusion Proteins, bcr-abl